Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Peripheral arterial disease affects around 20% of the UK population aged between 55 and 75 years. The most common symptom is intermittent claudication (IC). Individuals with IC have a cardiovascular risk three- to fourfold that of the non-claudicant population. Most patients can be managed successfully with lifestyle modification, including smoking cessation and physical exercise, together with antiplatelet therapy and good control of blood pressure and cholesterol levels. Patients with IC should also be screened for diabetes. Cilostazol is the only adjuvant drug therapy that has been shown in clinical trials to be effective in the treatment of IC.


Journal article


Practical Cardiovascular Risk Management

Publication Date





2 - 4